New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on October 10, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO Jack Khattar has recently sold 59,900 shares of Supernus Pharmaceuticals stock, amounting to a total transaction value of $3,029,336.
Recent Updates on SUPN stock
In the past 24 hours, Supernus Pharmaceuticals has seen significant analyst activity with Piper Sandler upgrading the stock to Overweight from Neutral and raising the price target to $65 from $40. This upgrade is attributed to the promising trajectory of Onapgo, Supernus’ apomorphine-based continuous subcutaneous infusion pump for advanced Parkinson’s disease, which launched in late April. The product’s potential for margin expansion and EBITDA growth, due to its non-promotion-intensive nature, has been highlighted as a key factor for the upgrade. Additionally, Cantor Fitzgerald raised its price target for Supernus to $63 from $46, further reflecting positive sentiment towards the company’s growth prospects.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals demonstrates strong financial health and operational efficiency, supported by robust earnings call highlights. However, technical indicators suggest overbought conditions, and the valuation appears stretched. The company’s future growth potential, driven by strategic acquisitions and product launches, is a significant positive factor.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
YTD Price Performance: 35.90%
Average Trading Volume: 823,234
Technical Sentiment Signal: Buy
Current Market Cap: $2.69B